EWEmma Borremose Wedervang

Emma Borremose Wedervang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emma Borremose Wedervang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Pradeesh Sivapalan

    Respiratory Medicine Section, Department of Medicine, Copenhagen University Hospital- Herlev and Gentofte, Hellerup, Denmark

    2 shared publications
  • Alexander Ryder Jordan

    Copenhagen Respiratory Research, Department of Medicine, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark

    1 shared publication
  • Alexandros G. Mathioudakis

    Division of Immunology, Immunity to Infection and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK

    1 shared publication
  • Andreas Fløe

    Department of Respiratory Diseases and Allergy, Aarhus University Hospital, 8200 Aarhus, Denmark

    1 shared publication
  • Anna Kubel Vognsen

    Copenhagen Respiratory Research, Department of Medicine, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark

    1 shared publication
  • Anna Kubel Vognsen

    Copenhagen Respiratory Research, Department of Medicine, Herlev and Gentofte Hospital, University of Copenhagen, 2900 Hellerup, Denmark

    1 shared publication

Latest Publications

  • Open Access

    Inhaled corticosteroids and risk of cardiovascular events in chronic obstructive pulmonary disease: a nationwide cohort study in Denmark

    by Mia Ritzau Ishøj Nielsen, Emma Borremose Wedervang, Anna Kubel Vognsen, Karen Hougaard Frost, Alexander Ryder Jordan, Sigrid Anna Aalberg Vikjord, Alexander G Mathioudakis, Jens-Ulrik Stæhr Jensen, Pradeesh Sivapalan

    Rationale: Cardiovascular disease is a major comorbidity in chronic obstructive pulmonary disease (COPD). Previous studies evaluating the association between inhaled corticosteroids (ICS) and cardiovascular events (CVEs) in COPD have yielded conflicting results and a potential dose–response relationship remains unclear. Objectives: To determine the association between ICS exposure and risk of CVE in COPD patients. Methods: In this nationwide, retrospective register-based cohort study, we included patients with a specialist-verified COPD diagnosis between January 2008 and January 2022. ICS exposure was quantified as mean daily budesonide-equivalent dose redeemed in the year prior to index and categorised as none, low (>0 µg/day and 800 µg/day). We assessed CVE risk using adjusted cause-specific Cox proportional hazards models, with additional sensitivity analyses including a complete-case analysis, time-varying Cox regression, Fine-Gray competing risk model, and a negative control outcome analysis. Results: Among 82 327 patients, 8948 (10.9 %) experienced a CVE during a 1-year follow-up. In the primary analysis, low- and moderate-dose ICS was associated with a significantly reduced CVE rate compared with no ICS use. A modest decrease in CVE rate was observed for moderate-dose ICS largely across all sensitivity analyses. Conclusion: ICS use in COPD was not associated with an increased risk of CVE at any dose level. A modest association with reduction in CVE risk was confined to moderate-dose ICS. These findings support the cardiovascular safety of ICS and reinforce that ICS prescribing should be guided by exacerbation risk and symptom burden rather than cardiovascular concern.

  • Open Access

    Inhaled Corticosteroids and Non-Tuberculous Mycobacteria Risk in Patients with COPD

    by Emma Moerk Borremose, Victor Naestholt Dahl, Anna Kubel Vognsen, Troels Lillebaek, Andreas Fløe, Tor Biering-Sørensen, Barbara Bonnesen, Josefin Eklöf, Pradeesh Sivapalan, Jens-Ulrik Stæhr Jensen

    Background/Objectives: Inhaled corticosteroids (ICS) increase the risk of pneumonia caused by various pathogens in patients with chronic obstructive pulmonary disease (COPD). Treatment may also increase the risk of infection with non-tuberculous mycobacteria (NTM), although evidence remains limited. The aim of this study was to assess the association between ICS treatment and the risk of NTM isolation among patients with COPD. Methods: This retrospective register-based cohort study included patients with a specialist-verified COPD diagnosis between 2008 and 2021. ICS exposure was based on redeemed prescriptions during the year preceding the index date. Exposure was calculated as the mean daily budesonide-equivalent dose and categorized as none, low, medium, or high. A cause-specific Cox proportional hazards regression model with death as a competing risk was applied, adjusted for potential confounders. Sensitivity analyses included, among others, an inverse probability of treatment weighted model, and a time-dependent Cox regression model. Results: A total of 120,006 patients were included, with a median follow-up time of 4.9 years. During follow-up, 378 (0.32%) patients reached the primary endpoint. Medium- and high-dose ICS were associated with an increased hazard of NTM isolation, with hazard ratios of 1.39 (95% CI 1.06–1.88, p = 0.020) and 1.52 (95% CI 1.14–2.04, p = 0.005), respectively. This association remained significant for high-dose ICS across all sensitivity analyses. Conclusions: In patients with COPD, ICS treatment was associated with an increased and dose-dependent hazard of NTM isolation, particularly at high doses. High-dose ICS should, therefore, be prescribed with caution.